Transcarent is a health tech company that empowers individuals and organizations to make informed, cost-effective decisions. Transcarent simplifies this complexity by providing a unified platform that aggregates healthcare services, resources, and data in one accessible interface. From finding the right specialist to understanding treatment options and estimating costs, Transcarent equips users with the tools they need to navigate their healthcare journey with confidence.
Transcarent has raised $126 million in Series D funding, bringing the company’s valuation to $2.2 billion. General Catalyst and 7wireVentures led the round, with participation from new investors Memorial Hermann Health System and Geodesic Capital. Moreover, former investors Human Capital, Kinnevik, Threshold Ventures, Ally Bridge Group, Alta Partners, Leaps by Bayer, and Merck Global Health Innovation Fund contributed to the Series D. In total, Transcarent has raised $450 million to date.
Transcarent, San Francisco, California, United States, was founded in 2020 by Glen Tullman. “Everyone asked, ‘Can you make it easier for our people to access high-quality, affordable care?’ and we have. Transcarent is the one place for health and care,” said Glen Tullman, Transcarent CEO. “One platform – your mobile phone – for everything you want and need. And an experience people don’t just like but love. High-quality care and cost reductions with a relentless focus on quality. Just what the doctor ordered.”
